Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allenrolfea occidentalis pollen extract is a biological allergen used for the diagnosis and treatment of Type I hypersensitivity reactions to iodine bush pollen. Iodine bush is a halophytic shrub common in the arid regions of the Southwestern United States and Mexico. The extract contains a complex mixture of proteins that, when administered in small amounts during skin testing, can identify sensitized individuals by eliciting a wheal-and-flare reaction. In therapeutic settings, the extract is used in allergen-specific immunotherapy (SIT), where increasing doses are administered subcutaneously to induce immunological tolerance. This process involves shifting the immune response from a Th2-mediated allergic profile to a Th1 or regulatory T-cell (Treg) profile, increasing the production of IgG4 blocking antibodies, and reducing the sensitivity of mast cells and basophils to the allergen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allenrolfea occidentalis pollen extract.